Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

NanoSphere Engages Chaé Manufacturing to Increase Production

C.NSHS

Vancouver, March 14, 2019 (GLOBE NEWSWIRE) -- NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES

(March 14, 2019)– NanoSphere Health Sciences Inc. (CSE: NSHS) (OTC: NSHSF) the biotechnology leader behind the patented NanoSphere Delivery System™, is pleased to announce the Company has engaged Chaé Manufacturing to help the Company meet increased demand for NanoSphere products in North America. 

NanoSphere is experiencing high demand for our new line of hemp CBD products, and we are also developing new cosmeceutical and anti-aging products for our distributors in the US, Canada and Mexico,” explained NanoSphere CEO Robert Sutton. “Our first order from our partners in Mexico, for example, is for 60,000 units of our CBD transdermal formula for pain, and we are expecting that will become a monthly shipment.”

Chaé Manufacturing (chaemanufacturing.com) is a premier manufacturing and fulfillment centre based in Colorado. It is the first and only company in the US to be “ToxicFree®” Certified. The ToxicFree standard means Chaé does not produce any product that contains potential carcinogenic ingredients such as parabens,  preservatives and propylene glycol. NanoSphere President and COO David Sutton says the agreement with Chaé allows NanoSphere to expand production as needed, while maintaining the Company’s dedication to production of health products that ‘do no harm’. 

“Chaé Manufacturing and their chief formulator Linda Chaé are the leaders in organic and non-toxic production of cosmeceutical products, and at the same time their fulfillment centre is geared up to allow for massive expansion of our Evolve Formulas’ line of products,” Sutton said. 

NanoSphere has developed a revolutionary multi-patented delivery system using smart lipid nanoparticles, known as the NanoSphere Delivery System™, that delivers cannabinoids  nutraceuticals, cosmeceuticals and pharmaceutical drugs into the human body through the skin or the mucosal membranes with greater bioactivity.  . For example, NanoSphere produces an award-winning, transdermal nano-particle gel that delivers cannabinoids through the skin to quickly relieve pain, inflammation and anxiety.  

Chaé Manufacturing founder Linda Chaé says she’s excited to be involved in bringing a cutting edge solution to the market. 

“NanoSphere is a pioneer in the use of nanotechnology for human health, and the clinical research is showing a major boost in the effectiveness of compounds like CBD and various medications  when the NanoSphere Delivery System™ is used,” Chaé said. “We think our participation will help NanoSphere’s growth, as we can provide help with research and development, scaled production, shipping and logistics, and help in registering new products in foreign or domestic markets.”

The first product line being formulated at Chaé will be NanoSphere’s Evolve Formulas’ transdermal NanoSerum™ Hemp CBD formula, used primarily to treat localized and systemic inflammation and pain.  NanoSphere and its Mexican distributor Abba Imports are currently going through the product registration process with national health regulator COFEPRIS, prior to shipping the first order to Mexico.

On behalf of the Board

David Sutton, President and COO

Mobile: 720.520.4283

E-mail: dsutton@NanoSpherehealth.com

Media Contact:

Gary Symons

Mobile: 250.300.9352

E-mail: gsymons@NanoSpherehealth.com

About NanoSphere

NanoSphere Health Sciences LLC, is a biotechnology firm specializing in the creation of the NanoSphere Delivery System™, a revolutionary platform using nanotechnology in the biodelivery of supplements, nutraceuticals and over-the-counter medications for the cannabis, pharmaceutical and animal health industries, and beyond. For more information on NanoSphere, please visit http://www.nanospherehealth.com.

About Evolve Formulas

Evolve Formulas is the provider of the world's first and only scientifically proven nanoparticle delivery system in cannabis. Evolve’s pioneering product, Transdermal NanoSerum™, is a fast-acting, ultra-strength transdermal formula infused with nano-encapsulated cannabis and cannabis extracts. For more information on Evolve Formulas, visit https://www.evolveformulas.com/. Follow us on Facebook, Instagram and Twitter.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

Forward Looking Statement Caution

This news release includes forward looking statements that are subject to assumptions, risks and uncertainties. Statements in this news release which are not purely historical are forward looking statements, including without limitation any statements concerning the Company's intentions, plans, estimates, expectations or beliefs regarding the future. Although the Company believes that any forward looking statements in this news release are reasonable, there can be no assurance that any such forward looking statements will prove to be accurate. The Company cautions readers that all forward looking statements, including without limitation those relating to the Company's future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward looking statements. Without limitation, these include assumptions, risks and uncertainties inherent in completing sub-licensing arrangements in the United States, Canada and abroad, product demand, production, competition and government regulation of the Cannabis industry, any and all of which may have an adverse effect on the Company’s expansion plans, sales, revenues and its financial results and condition.  Readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance on forward looking statements. Any forward looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward looking statements, or to update the reasons why actual events or results could or do differ from those projected in the forward looking statements, whether as a result of new information, future events or otherwise.

Gary Symons Nanosphere Health Sciences 2503009352 gsymons@nanospherehealth.com 


Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today